Trial findings do not support prasugrel monotherapy at the time of primary PCI for STEMI patients
Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.